Clear science for curious people
ScienceBlog.com
Writer at Science Blog

ScienceBlog.com

Contributor

Profile →

Health

John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting

HACKENSACK, N.J. (June 3, 2010) -- The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 4 -- 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma. These findings are only three of 16 studies that will be discussed by researchers from the John Theurer Cancer Center. "We are excited to present significant research findings, particularly in the area of hematological malignancies, as part of our continued commitment to advance cancer research," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, John Theurer Cancer Center. "The studies we will present at ASCO represent just a small sample of the work that we do to improve outcomes not just for our patients, but for the cancer community as a whole." Research to be presented at ASCO by researchers at the John Theurer Cancer Center will showcase treatment advancements for cancers of the blood, including lymphoma and multiple myeloma. Poster presentation highlights in these areas include: Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) combination may help patients with relapsed indolent B-cell lymphoma. (Abstract number 8078; poster session, June 5, 8:00 a.m. -- 12:00 p.m.) Andre Goy, M.D., Deputy Director and Chief, Lymphoma at the John Theurer Cancer Center collaborated with researchers at other major cancer centers to examine the value of adding rituximab to FND (fludarabine, mitoxantrone, and dexamethasone) combination therapy for relapsed indolent B-cell lymphoma. While rituximab is often used as a treatment option for patients with this condition, optimal therapy remains controversial. In phase I-II studies by this research group, they observed a complete remission rate of 48% using FND for this cancer. Adding rituximab to the treatment regimen, they achieved a five-year overall survival rate of 84% and a nine-year rate of 53%. The researchers concluded that rituximab-FND combination therapy is a very active and well tolerated regimen for relapsed indolent B-cell lymphoma. Patients who received this therapy were also able to receive stem cell transplants, and had favorable outcomes. Optimal front-line therapies for mantle cell lymphoma. (Abstract number 8067; poster session, June 5, 8:00 a.m. -- 12:00 p.m.) Tatyana Feldman, M.D., Attending, Lymphoma, the John Theurer Cancer Center and colleagues conducted a retrospective analysis of cases at the John Theurer Cancer Center in order to compare the survival of newly diagnosed mantle cell lymphoma patients who were given three distinct first-line treatment regimens. The study was conducted because there is no consensus on the best treatment for this subset of patients, and because data from randomized studies are not available. Recent analyses however, strongly support the use of high-dose treatments for these patients. The researchers' analyzed data to compare the overall survival of patients treated with rituximab plus a combination of doxorubicin, cyclophosphamide, vincristine, and dexamethasone (R-HCVAD); high-dose chemotherapy followed by autologous stem cell transplantation; and standard-dose chemotherapy with rituximab. Patients treated with either R-HCVAD or stem-cell transplantation had better survival rates than the patients treated with standard-dose chemotherapy and rituximab. The researchers concluded that both R-HCVAD and high-dose chemotherapy combined with autologous stem cell transplantation provide a platform for treatment strategies that integrate novel therapies, or as part of a maintenance strategy. Is the Mantle Cell Lymphoma International Prognostic Index (MIPI) adequate to stage this cancer? (Abstract number 8092; poster session, June 5, 8:00 a.m. -- 12:00 p.m.) In this study, Anthony Mato, M.D., Attending, Lymphoma, the John Theurer Cancer Center and his colleagues looked at the usefulness of a tool known as the Mantle Cell Lymphoma International Prognostic Index (MIPI) for guiding treatment strategies for mantle cell lymphoma, a difficult-to-treat non-Hodgkin lymphoma. The index is used to classify patients into "low," "intermediate" and "high" risk groups in order to stage the cancer and determine the best treatment strategy. Although MIPI has been validated in other studies, conflicting results on using MIPI to guide an aggressive therapy known as "HCVAD" led the researchers to investigate further. They conducted a single-center, retrospective cohort study to identify predictors of survival in patients treated with first-line rituximab-plus-HCVAD (R-HCVAD), alternating with rituximab-methotrexate-AraC (R-MTX-AraC), another combination therapy. Although the study is still ongoing, the researchers found that MIPI did not identify the three distinct staging categories with respect to patients' overall survival or progression-free survival, the primary endpoints for this study. Dr. Mato and colleagues are collaborating with another center to verify their results. Future work will focus on identifying molecular markers for failure in mantle cell lymphoma patients treated with dose-intensive regimens. Vorinostat proves safe and tolerable for treating various cancers. (Abstract number e13600; publication-only abstract) David S. Siegel, M.D., Ph.D., Co-Chief, Multiple Myeloma at the John Theurer Cancer Center and colleagues will present their analyses of safety and tolerability data from Phase I and II studies of vorinostat. Vorinostat is a medication that is FDA approved to treat skin problems related to cutaneous T-cell lymphoma when other treatments have not been effective. It is a histone deacetylase (HDAC) inhibitor, the first in a class of drugs that regulate enzymes involved in cell signaling. Vorinostat is also being investigated as a treatment option for a range of other solid and hematologic malignancies. The researchers looked at safety and tolerability data from patients in phase I and II Merck-sponsored clinical trials who received vorinostat as a single (monotherapy) or combination therapy for a variety of cancers. Data from these unblinded trials showed that vorinostat has an acceptable safety and tolerability profile when given as monotherapy, or more commonly in a combination regimen, for patients with refractory metastatic cancer. Denileukin diftitox shows promise for newly diagnosed T-cell lymphoma patients (the CONCEPT trial). (Abstract number 8045; poster session, June 4, 5:00 -- 6:00 p.m.) As part of the multicenter CONCEPT trial, Dr. Goy tested the efficacy and safety of denileukin diftitox, a genetically engineered fusion protein that targets cancers that express the interleukin-2 receptor. The drug was tested head-to-head against the standard "CHOP" (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy regimen in a Phase II study in which the patients receiving the new drug were also treated with CHOP. The study group consisted of patients newly diagnosed with aggressive T-cell lymphomas. Researchers found the combination therapy effective, with a 68% overall response rate and 57% complete response rate. As a result, they are starting a multicenter comparison study. About the John Theurer Cancer Center at Hackensack University Medical Center The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancer. The 15 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of after care services that distinguish the John Theurer Cancer Center from other facilities. For more information please go to humccancer.org.

Jun 4, 2010

Earth & Environment

U of Minnesota researcher finds that flooring can affect how consumers make purchase decisions

From teachers to hairdressers, people who stand on their feet all day will tell you that the flooring beneath them can be the difference between a good day and a bad one. But can the difference between carpet and hard tile flooring affect how you make decisions? Research published this month by Joan Meyers-Levy, a professor of marketing at the University of Minnesota's Carlson School of Management, and author of the famed ceiling height study, suggests that the way people judge products may be influenced by the ground beneath them. In the study, published in the June 2010 issue of the Journal of Consumer Research, authors Meyers-Levy and Juliet Zhu and Lan Jiang (University of British Columbia) explored the feelings evoked by the two most common flooring types in retail environments: hard vinyl tile and carpet. "When a person stands on carpeted flooring, it feels comforting," says Meyers-Levy. "But the irony is that when people stand on carpet, they will judge products that are close to them as less comforting." The authors first conducted a study to show that carpeting truly does evoke a greater sense of physical comfort than tiled flooring. "Given this finding, we then tackled a more practical and intriguing question," says Meyers-Levy. "Would these bodily sensations elicited by the flooring transfer to people's assessments of products that they observe while shopping?" The researchers had participants stand on either soft pile carpet or hard tile and view products that were either close to them or moderately far away. When the products were a moderate distance away, people's judgments of them were unconsciously guided by their bodily sensations. That is, if they were standing on soft carpet and viewed a product that was moderately far away, they judged that item's appearance to be comforting. However, people who examined products while standing on this same plush carpet judged items that were close by as being less comforting than they did if the products were moderately far away. "When we look at objects that are close by, the bodily sensations elicited by the flooring are more likely to be used as a comparison standard, not an interpretive frame," states Meyers-Levy. These findings have important implications for all brick and mortar retailers and service providers. Elements of interior décor such as flooring are more than matters of function or style. They may be directly tied to how a consumer perceives products, and that can determine whether or not the consumer purchases the good. Standing on solid ground with your consumers has always been important, but this research suggests that it may be the difference between a sale and failure to close the deal. "Context Effects from Bodily Sensations: Examining Bodily Sensations Induced by Flooring and the Moderating Role of Product Viewing Distance." is forthcoming in the Journal of Consumer Research in June 2010. Joan Meyers-Levy is the Holden-Werlich School-Wide Professor of Marketing at the Carlson School. Her research examines a variety of consumer behavior issues related to visual and verbal communication, memory, information processing, and gender, as well as individual differences. The Institute for Research in Marketing is part of the Carlson School of Management at the University of Minnesota. Established in 2005, the Institute fosters innovative, rigorous research that improves the science and practice of marketing. More information can be found at http://www.carlsonschool.umn.edu/marketinginstitute.

Jun 3, 2010

Health

Stage II and stage III colon cancer patients treated after 1995 have improved overall survival

CHICAGO -- Patients with stage III colon cancer treated with 5-FU-based chemotherapy after complete surgical removal of their tumor after 1995 had improved overall survival with no change in time to recurrence compared to patients treated before 1995. In contrast, patients with stage II colon cancer treated after 1995 had longer time to recurrence and time from recurrence to death compared to those patients treated prior to 1995, according to Mayo Clinic and Gr Hospitalier Pitie-Salpetriere, Paris, researchers. They will present the study's findings on June 4-8, 2010, at the American Society of Clinical Oncology (http://www.asco.org/) annual meeting in Chicago. "By combining information from 21 cancer treatment trials for patients with stage II and stage III colon cancer, our analysis determined that those patients treated after 1995 had improved overall survival," says Dan Sargent, Ph.D., Mayo Clinic biostatistician, North Central Cancer Treatment Group (http://ncctg.mayo.edu/) (NCCTG) statistician and senior author on the study. The analysis compared patient data from more than 18,000 patients with stage II and stage III colon cancer treated with 5-FU-based chemotherapy after their primary tumor had been surgically removed for the time period 1978-1995 versus 1996-2007. "Patients with stage II colon cancer treated after 1995 had had longer time to recurrence, possibly due to improvements in surgery and pathology" says Dr. Sargent. "In addition, after 1995, both stage II and stage III colon cancer patients treated after surgery with the same 5-FU-based chemotherapy after surgery had improved overall survival. This finding provides evidence to support previous findings that access to new medical therapies introduced in the mid-1990s as well as the expanded use of surgery for patients recurrent disease have meaningfully improving overall survival for patients treated in this setting." The findings arise from analysis of combined data collected within an expanded database by the Adjuvant Colon Cancer End Points (ACCENT) Group, a consortium of scientists. The ACCENT database includes data from more than 33,500 patients from the United States, Canada, Australia and Europe. ACCENT, chaired by Dr. Sargent, is supported by the NCCTG. Dr. Sargent conducted the analysis on the expanded database in concert with an international team of scientists participating in ACCENT including Qian Shi, Ph.D. and Brian Bot, from Mayo Clinic; Thierry Andre, M.D., Gr Hospitalier Pitie-Salpetriere; Greg Yothers, M.D., NSABP Statistical Center, Pittsburgh; Daniel Haller, M.D., Abramson Cancer Center, University of Pittsburgh; Eric Van Cutsem, M.D., Ph.D., University Hospital Gasthuisberg/Leuven; James Cassidy, M.D., Glasgow University; Jacqueline Benedetti, Ph.D., Fred Hutchinson Cancer Research Center, Seattle; and Michael O'Connell, M.D., National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation, NSABP Operations Center, Pittsburgh. About Mayo Clinic For more than 100 years, millions of people from all walks of life have found answers at Mayo Clinic. These patients tell us they leave Mayo Clinic with peace of mind knowing they received care from the world's leading experts. Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. At Mayo Clinic, a team of specialists is assembled to take the time to listen, understand and care for patients' health issues and concerns. These teams draw from more than 3,700 physicians and scientists and 50,100 allied staff that work at Mayo Clinic's campuses in Minnesota, Florida, and Arizona; and community-based providers in more than 70 locations in southern Minnesota, western Wisconsin and northeast Iowa. These locations treat more than half a million people each year. To best serve patients, Mayo Clinic works with many insurance companies, does not require a physician referral in most cases and is an in-network provider for millions of people. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your general health information. VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Dan Sargent, are available on the Mayo Clinic News Blog (http://newsblog.mayoclinic.org/2010/06/03/patients-with-stage-ii-and-stage-iii-colon-cancer-treated-with-5-fu-based-adjuvant-therapy-after-1995-have-improved-overall-survival/). ASCO Abstract Number: 3616 (http://abstract.asco.org/AbstView_74_50544.html)

Jun 3, 2010

Health

Cell Transplantation reports consistent and successful islet isolations offer diabetes hope

Tampa, Fla. (June 3, 2010) -- A team of researchers from several collaborating Baylor University research centers and from Japan's Okayama Graduate School of Medicine have found a way to more consistently isolate pancreatic islet cells from brain dead donors using ductal injection (DI), a process that immediately cools donor islet cells at the injection site. The more successful islet isolation process resulted in the three type 1-diabetes patients, who received islet cell transplants, becoming insulin independent. Their study is published in issue 19(3) of Cell Transplantation and it is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ . "Inconsistent islet isolation is one of the important issues in clinical islet transplantation," said Dr. Shinichi Matsumoto, the research team's lead author. "Failure of donor islet isolation often results from the loss of the donor pancreas. Our simple modification of the retrieval process appears valuable for assuring greater success in islet transplantation." Ductal injection is a procedure that modifies the islet isolation process using a cooling solution on the pancreatic islet cells derived from brain-dead donors. The cooling solution, applied at the donor's pancreatic ductal site, aids the viability of the islet cells. The team successfully isolated islet cells in the DI group seven times while only three out of eight islet cell groups were isolated in the nonductal injection group. When islets from the DI group were transplanted into three type 1 diabetic patients, all three became insulin independent. "DI significantly improved the quantity and quality of isolated islets and resulted in a high success rate of clinical islet transplantation," said Dr. Matsumoto. According to the research team, a fifty percent success rate for clinical islet isolation has been standard; they were able to achieve a better than 80 percent success rate using DI. The team reported that there were no significant demographic or clinical differences in the two patient groups receiving islet transplants, nor were there significant differences in the donated pancreata. All donor pancreata were preserved for less than six hours. Each patient received two islet preparations. "In the DI group, the fasting blood glucose of all three patients improved after a single islet transplantation, and improved further after the second transplantation," commented Dr. Matsumoto. "None of these patients experienced subsequent hypoglycemia, and all three became insulin independent." The team had recently shown that the DI process was successful in animal models because DI prevented tissue and cell death, suggesting that DI improved the quality and quantity of the isolated islet cells destined for transplantation. "The number of islets isolated from donor pancreata continues to be quite variable and many times are not sufficient for clinical transplantation" said Dr. Rodolfo Alejandro, section editor for Cell Transplantation and Professor of Medicine at the University of Miami Miller School of Medicine. "This paper describes a novel approach to improve islet isolation yields. These are promising results that need to be confirmed in a randomized concurrent protocol". Contact: Dr. Shinichi Matsumoto, Baylor All Saints Medical Center, Baylor Research Institute 1400 8th Avenue, Fort Worth, Texas 76104, USA. Tel: 817-922-2570 Fax 817-922-4645 Email: [email protected] The editorial offices for Cell Transplantation are at the Center of Excellence for Aging and Brain Repair, College of Medicine, the University of South Florida and the Diabetes Research Institute, University of Miami Miller School of Medicine. Contact, David Eve, PhD. at [email protected] or Camillo Ricordi, MD at [email protected] News release by Randolph Fillmore, www.sciencescribe.net

Jun 3, 2010

Health

ASU instrument on NASA rover helps identify outcrop of long-sought rare rock on Mars

TEMPE, Ariz. -- It's amazing what cleaning your glasses can reveal. A mineral-scouting instrument developed at Arizona State University has found an outcrop of rock rich in carbonates in the Columbia Hills of Gusev Crater on Mars, according to a report published online June 3 in the journal Science. The instrument is onboard NASA's Mars Exploration Rover Spirit. What makes the discovery unusual is that Spirit visited the outcrop, dubbed Comanche, back in December 2005. Yet the data pointing to the discovery languished since then because one of the instruments that detected the carbonate minerals was partly blinded by dust. Dust in your eye The instrument is the Miniature Thermal Emission Spectrometer, or Mini-TES, developed at Arizona State University. Each of the two Mars rovers carries a Mini-TES to identify minerals in rocks nearby. The instrument was designed by its Principal Investigator, Philip Christensen, an ASU Regents' Professor in the School of Earth and Space Exploration, part of the College of Liberal Arts and Sciences. "Mini-TES got dusted months before Spirit reached Comanche, and we didn't have a good way to correct for the dust effects at the time," says Steve Ruff, research scientist at ASU's Mars Space Flight Facility. Ruff is one of a team of scientists on the paper, whose lead author is Richard V. Morris of NASA's Johnson Space Center in Houston. "We knew there was something weird about the outcrop's spectrum as seen by Mini-TES, but couldn't say what caused it." Ruff adds, "Spirit's Mössbauer spectrometer indicated that carbonate was possible, but I didn't believe it." What finally did the trick was developing a calibration to remove the spectral effects of the dust on the instrument. Combined with the Mössbauer data and chemical data from a third spectrometer, "the Mini-TES spectra put the discovery over the edge," says Ruff Warmer, wetter Mars? Scientists have been searching for Martian carbonate rocks for decades because such minerals are crucial to understanding the early climate history of Mars and the related question of whether the planet might once have held life. "Small amounts of carbonate minerals have been detected on Mars before," says Ruff. The difference this time, he says, "is that we're seeing a couple of large outcrops of rock poking through the soil of the Columbia Hills. The rocks are about 25 percent carbonate by weight, by far the highest abundance we've seen on Mars." Born of water Comanche and a neighboring small outcrop dubbed Comanche Spur have the same granular texture and Mini-TES spectral nature. Ruff says they are part of a stack of volcanic sedimentary rocks, draped over the underlying terrain. "They're definitely a puzzle to understand," says Ruff. "The outcrops are very rich in olivine, a volcanic mineral, but they appear to have been soaked in water." He explains that it's as if the granular material settled over a preexisting landscape, then the entire stack was flooded with carbonate-rich water, probably from a hydrothermal source. NASA's other Mars rover, Opportunity, has discovered ample evidence for alteration of rocks by water in Meridiani Planum, on the other side of Mars from Spirit's Gusev Crater. But the water at Meridiani was strongly acidic. While life can evolve to survive in acidic conditions -- such as in some of Yellowstone National Park's geysers and hot springs -- few scientists think it can start under those conditions. Moreover, acidic water quickly destroys carbonate minerals, as for example vinegar dissolves hard water deposits. Thus finding outcrops of carbonate rock shows that the hydrothermal water at Comanche was liquid, chemically neutral, and abundant. While there's no evidence for life, Ruff says, the conditions would have been more favorable for it. In plain view Ironically, Ruff notes, the new finding complicates the story of the Columbia Hills. "This makes the geology harder to understand. It adds another environment to incorporate into the picture of how the Hills formed," he says. Looking at the big picture, Ruff notes, "the Comanche data have been available to scientists and the public for about four years now. The new finding shows that this data set still harbors potentially major discoveries. "Do other surprises await us? Who knows? But I'll make a strong prediction: More discoveries will be made with old data."

Jun 3, 2010

Earth & Environment

Early Earth haze likely provided ultraviolet shield for planet, says CU-Boulder study

A new study shows a thick organic haze that enshrouded early Earth several billion years ago may have been similar to the haze now hovering above Saturn's largest moon, Titan, and would have protected primordial life on the planet from the damaging effects of ultraviolet radiation. The University of Colorado at Boulder scientists believe the haze was made up primarily of methane and nitrogen chemical byproducts created by reactions with light, said CU-Boulder doctoral student Eric Wolf, lead study author. Not only would the haze have shielded early Earth from UV light, it would have allowed gases like ammonia to build up, causing greenhouse warming and perhaps helped to prevent the planet from freezing over. The researchers determined the haze of hydrocarbon aerosols was probably made up of fluffy, microscopic particles shaped somewhat like cottonwood tree seeds that would have blocked UV but allowed visible light through to Earth's surface, Wolf said. Prior to the new study, the prevailing scientific view was that the atmosphere of Earth some 3 billion years ago was primarily made up of nitrogen gas with lesser amounts of carbon dioxide, methane, hydrogen and water vapor, said Wolf. "Since climate models show early Earth could not have been warmed by atmospheric carbon dioxide alone because of its low levels, other greenhouse gases must have been involved. We think the most logical explanation is methane, which may have been pumped into the atmosphere by early life that was metabolizing it." A paper on the subject by Wolf and CU-Boulder Professor Brian Toon of the atmospheric and oceanic sciences department is being published in the June 4 issue of Science. NASA's Planetary Atmosphere Program funded the study. The output of the sun during the Archean period some 3.8 billion to 2.5 billion years ago is thought to have been 20 percent to 30 percent fainter than today, said Wolf. But previous work by other scientists produced geological and biological evidence that indicates Earth's surface temperatures were as warm or warmer than today. As part of the early Earth study, Wolf and Toon used a climate model from the National Center for Atmospheric Research and concepts from lab studies by another CU group led by chemistry and biochemistry Professor Margaret Tolbert that help explain the odd haze of Titan, the second largest moon in the solar system and the largest moon of Saturn. Titan came under intense study following the arrival of the Cassini spacecraft at Saturn in 2004, allowing scientists to determine it was the only moon in the solar system with both a dense atmosphere and liquid on its surface. Previous modeling efforts of early Earth haze by other scientists assumed that aerosol particulates making up the haze were spherical, said Wolf. But the spherical shape does not adequately account for the optical properties of the haze that blanketed the planet. Lab simulations helped researchers conclude that the Earth haze likely was made up of irregular "chains" of aggregate particles with greater geometrical sizes than spheres, similar to the shape of aerosols believed to populate Titan's thick atmosphere. Wolf said the aggregate aerosol particulates are believed to be fragmented geometric shapes known as fractals that can be split into parts. During the Archean period there was no ozone layer in Earth's atmosphere to protect life on the planet, said Wolf. "The UV shielding methane haze over early Earth we are suggesting not only would have protected Earth's surface, it would have protected the atmospheric gases below it -- including the powerful greenhouse gas, ammonia -- that would have played a significant role in keeping the early Earth warm." CU-Boulder researchers estimated there were roughly 100 million tons of haze produced annually in the atmosphere of early Earth during the Archean. "If this was the case, an early Earth atmosphere literally would have been dripping organic material into the oceans, providing manna from heaven for the earliest life to sustain itself," Toon said. "Methane is the key to make this climate model run, so one of our goals now is to pin down where and how it originated," said Toon. If Earth's earliest organisms didn't produce the methane, it may have been generated by the release of gasses during volcanic eruptions either before or after life first arose -- a hypothesis that will requires further study, he said. The new CU-Boulder study will likely re-ignite interest in a controversial experiment by scientists Stanley Miller and Harold Urey in the 1950s in which methane, ammonia, nitrogen and water were combined in a test tube. After Miller and Urey ran an electrical current through the mixture to simulate the effects of lightning or powerful UV radiation, the result was the creation of a small pool of amino acids -- the building blocks of life. Toon said the theory of early Earth being shrouded by a gaseous blanket containing methane and ammonia first arose in the 1960s and was subsequently discarded by scientists. In the 1970s and 1980s some scientists suggested the early Earth atmosphere was similar to those on Mars and Venus with lots of carbon dioxide, another theory that eventually went by the wayside. Since CO2-rich atmospheres do not produce organic molecules easily, scientists began looking in deep-sea volcanic vents and at wayward asteroids to explain early Earth life. A 1997 paper by the late Carl Sagan of Cornell University and Christopher Chyba, then at the University of Arizona, proposed that an organic aerosol shield in early Earth's atmosphere would have protected the ammonia wafting beneath it, allowing heating to occur at Earth's surface. But the authors proposed the haze particles were spherical rather than irregular aggregate particles Wolf and Toon suggest and did not consider methane to be the driver of the system, eventually sinking that theory. "We still have a lot of research to do in order to refine our new view of early Earth," said Wolf. "But we think this paper solves a number of problems associated with the haze that existed over early Earth and likely played a role in triggering or at least supporting the earliest life on the planet." From space, early Earth probably looked much like Titan looks today, said Toon. "It would have been shrouded by a reddish haze that would have been difficult to see through, and the ocean probably was a greenish color caused by dissolved iron in the oceans. It wasn't a blue planet by any means."

Jun 3, 2010

Health

Mount Sinai researchers approaching universal treatment for all strains of influenza

Researchers at Mount Sinai School of Medicine have discovered a novel component of the influenza virus that may be the key to disabling the virus's ability to replicate itself and to developing a universal anti-viral treatment. The findings were published June 1 online in Proceedings of the National Academy of Sciences. The influenza A virus is encoded by eight individual single-stranded segments of RNA. Each segment must serve as the material for both making protein and new segments, processes called transcription and replication. As each strand must perform both functions, it is imperative that the virus prioritize these processes, starting with transcription and then switching to replication. Mount Sinai researchers have, for the first time, identified a small-viral RNA (svRNA), derived from the virus, that is integral to the switch from transcription to replication. Inhibiting svRNA from making this switch would stymie replication and thus slow or halt the spread of the virus. Because segment ends and replication strategies used for influenza B and C are similar to those of influenza A, this discovery can lead to a universal treatment for people suffering from the disease. It would also be effective against the H1N1 swine flu virus. "The implications of this study are very exciting," said Benjamin tenOever, PhD, Assistant Professor of Microbiology at Mount Sinai School of Medicine and corresponding author of the study. "While each segment encodes different viral products, the svRNAs remain consistent, both between segments and across viral strains. If we can block the availability of svRNA we can inhibit the switch to replication, thereby stopping viral spread. As an added bonus, if the virus remains stuck in transcription, it will continue to produce proteins, ultimately strengthening the antibody response." The small RNA component was originally identified through a process called deep sequencing. This revolutionary new technique allows scientists to obtain millions of small RNAs from cells in a completely unbiased fashion. The technique was applied to lung cells infected with influenza A virus and ultimately led to the discovery of the first small RNA component ever identified from this family of viruses. "Questions remain about exactly how the svRNAs function," said Dr. tenOever. "We're also hoping to engineer a means of delivering RNA-based antagonists into the body's system as a means of inhibiting svRNA function. We're still a few years off from solving the entire puzzle. However, by finding this one piece, a universal treatment for all strains of influenza is within reach of becoming a reality." About The Mount Sinai Medical Center The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges. The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2009, U.S. News & World Report ranked The Mount Sinai Hospital among the nation's top 20 hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place. For more information, visit www.mountsinai.org.

Jun 3, 2010

Health

Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO

Hackensack, NJ, June 03, 2010 -- The John Theurer Cancer Center at Hackensack University Medical Center announced today that its physicians and researchers will present 16 abstracts on treatment and diagnostic progress in many different areas of oncology during the Annual Meeting of American Society of Clinical Oncology (ASCO) in Chicago, IL from June 4-8. "At the John Theurer Cancer Center, we're dedicated to providing extraordinary cancer care to our patients, which includes conducting high-quality cancer research and cutting-edge clinical trials," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, the John Theurer Cancer Center. "We're pleased to add to an important body of research at this premier oncology conference." Abstracts from the John Theurer Cancer Center research that are scheduled to be presented include: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM). (8031) (Poster Discussion Session) - Friday, June 4 from 2:00 p.m. - 6:00 p.m. in E450a Phase II study of denileukindiftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. (8045) (Poster Discussion Session) - Friday, June 4 from 2:00 p.m. - 6:00 p.m. in E450a Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). (8038) (Poster Discussion Session) - Friday, June 4 from 2:00 p.m. - 6:00 p.m. in E450a The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC). (8092) (General Poster Session) -- Saturday, June 5 from 8:00 am -- 12:00 p.m. in S Hall A2 Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL). (8067) (General Poster Session) -- Saturday, June 5 from 8:00 am -- 12:00 p.m. in S Hall A2 Impact of high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03. (10546) (General Poster Session) -- Saturday, June 5 from 8:00 am -- 12:00 p.m. in S Hall A2 Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL). (8053) (General Poster Session) -- Saturday, June 5 from 8:00 am -- 12:00 p.m. in S Hall A2 Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI). (8135) (General Poster Session) -- Saturday, June 5 from 8:00 am -- 12:00 p.m. in S Hall A2 Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). (8078) (General Poster Session) -- Saturday, June 5 from 8:00 am -- 12:00 p.m. in S Hall A2 Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study. (8125) (General Poster Session) -- Saturday, June 5 from 8:00 am -- 12:00 p.m. in S Hall A2 Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM). (8133) (General Poster Session) -- Saturday, June 5 from 8:00 am -- 12:00 p.m. in S Hall A2 Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD. (8006) (Oral Abstract Session) - Saturday, June 5 from 1:00 p.m. -- 4:00 p.m. in E354a Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study. (8003) (Clinical Science Symposium) Saturday, June 5 from 4:30 p.m. -- 6:00 p.m. in E354a Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). (8001) (Clinical Science Symposium) Saturday, June 5 from 4:30 p.m. -- 6:00 p.m. in E354a Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). (8000) (Clinical Science Symposium) Saturday, June 5 from 4:30 p.m. -- 6:00 p.m. in E354a ASCO is the world's leading professional organization representing physicians who treat those with cancer. ASCO's members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. About the John Theurer Cancer Center at Hackensack University Medical Center The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancer. The 15 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of after care services that distinguish the John Theurer Cancer Center from other facilities. For more information please go to humccancer.org.

Jun 3, 2010

Health

Key nutrient in maternal diet promises 'dramatic' improvements for people with Down syndrome

ITHACA, N.Y. -- A nutrient found in egg yolks, liver and cauliflower taken by mothers during pregnancy and nursing may offer lifelong "dramatic" health benefits to people with Down syndrome . A new study done at Cornell University and published June 2 in the peer-reviewed journal Behavioral Neuroscience found that more choline during pregnancy and nursing could provide lasting cognitive and emotional benefits to people with Down syndrome. The work indicated greater maternal levels of the essential nutrient also could protect against neurodegenerative conditions such as Alzheimer's disease. "We found that supplementing the maternal diet with additional choline resulted in dramatic improvements in attention and some normalization of emotion regulation in a mouse model of Down syndrome," said lead author Barbara Strupp, professor of nutritional sciences and of psychology. In addition to mental retardation, Down syndrome individuals often experience dementia in middle age as a result of brain neuron atrophy similar to that suffered by people with Alzheimer's disease. Strupp said the improved mental abilities found in the Down syndrome mice following maternal choline supplements could indicate protection from such neurodegeneration "in the population at large." Strupp and her co-authors tested Down syndrome-model mice born from mothers that were fed a normal diet versus those given choline supplements during their three-week pregnancy and three-week lactation period. They also examined normal mice born from mothers with and without additional choline. The choline-supplemented mothers received about 4.5 times more choline (roughly comparable to levels at the higher range of human intake) than unsupplemented mothers. Beginning at 6 months of age, the mice performed a series of behavioral tasks over a period of about six months to assess their impulsivity, attention span, emotional control and other mental abilities. The researchers found the unsupplemented Down syndrome-model mice became more agitated after a mistake than normal mice, jumping repeatedly and taking longer to initiate the next trial. The choline-supplemented Down syndrome-model mice showed partial improvement in these areas. "I'm impressed by the magnitude of the cognitive benefits seen in the Down syndrome-model mice," Strupp said. "Moreover, these are clearly lasting cognitive improvements, seen many months after the period of choline supplementation." Strupp said the results are consistent with studies by other researchers that found increased maternal choline intake improves offspring cognitive abilities in rats. However, this is the first study to evaluate the effects of maternal choline supplementation in a rodent model of Down syndrome. Previous studies of humans and laboratory animals have shown that supplementing the diets of adults with choline has proven to be largely ineffective in improving cognition. "Although the precise mechanism is unknown, these lasting beneficial effects of choline observed in the present study are likely to be limited to increased intake during very early development," Strupp said. The study, funded in part by the National Institutes of Health, was part of the dissertation of Cornell doctoral candidate Jisook Moon. Other Cornell collaborators included Myla Strawderman, research associate in nutritional sciences, and David Levitsky, professor of nutrition and psychology. Strupp and collaborators have received additional NIH funding to study the neural mechanisms underlying the results observed in this study.

Jun 3, 2010

Health

New study shows that the major events of the Jewish diaspora can be seen in the genomes of the Jewish people

(New York, NY, June 3, 2010) Through the use of sophisticated genomic analysis, researchers at NYU Langone Medical Center have found that the genetic influences of the Jewish people have retained their genetic coherence, as well as their cultural and religious traditions, even as Jewish communities migrated from the Middle East into Europe, North Africa and across the world according to a new study in the American Journal of Human Genetics. "Previous genetic studies based upon blood group and serum markers suggested that Jewish groups originated in the Middle Eastern with greater genetic similarity between groups of Jewish populations," says Harry Ostrer, MD, professor of Pediatrics, Pathology and Medicine at NYU Langone Medical Center and senior author of the paper. "We have shown that despite the fact that individuals from the Diaspora have distinctive features that are representative of each group's genetic history, they also share a set of common genetic threads." Dr. Ostrer and colleagues performed a genome wide analysis of Iranian, Iraqi, Syrian, Italian, Turkish, Greek and Ashkenazi Jews and compared these results with non-Jewish groups. The researchers identified distinct Jewish population clusters that each exhibited a shared Middle Eastern ancestry, proximity to contemporary Middle Eastern populations and variables degrees of European and North African genetic intermingling. Yet, amid all of these differences, the Jewish groups were more related to each other than to the non-Jewish groups in the study and were more likely to share long threads of DNA. The study also demonstrated that the history of Jewish people could be found in their genomes. The two major groups, Middle Eastern Jews and European Jews, were timed to have diverged from each other approximately 2500 years ago. Southern European populations show the greatest proximity to Ashkenazi, Sephardic and Italian Jews, reflecting the large-scale southern European conversion and admixture known to have occurred over 2,000 years ago during the formation of the European Jewry. An apparent North African ancestry component was also observed as was present in the Sephardic groups potentially reflecting gene flow from Moorish to Jewish populations in Spain from 711 to 1492. The structure of the genomes of Ashkenazi Jewish populations indicates a severe bottleneck followed by expansion during the 19th century when the Jewish population in western and eastern Europe increased about twice as fast as the non-Jewish population. This has been referred to as "the demographic miracle." Within every Jewish group, there was a high degree of relatedness between any two of its members. For Ashkenazi Jews, the relatedness was similar to what one might observe for fifth cousins. Dr. Ostrer noted, "The study supports the idea of a Jewish people linked by a shared genetic history. Yet the admixture with European people explains why so many European and Syrian Jews have blue eyes and blonde hair. " Co-authors of the study include Gil Atzmon, Bernice Morrow and Edward Burns of Albert Einstein College of Medicine, Itsik Pe'er and Pier Francesco Palamara of Columbia University, Eitan Friedman of Chaim Sheba Medical Center in Israel as well as Christopher Velez, Li Hao, Alexander Pearlman and Carole Oddoux of NYU Langone Medical Center. The study is the first from the Jewish HapMap Project, a joint endeavor of NYU School of Medicine and Albert Einstein College of Medicine of which the goal is to understand the structure of the genomes in the Jewish populations. The research was funded by the Lewis and Rachel Rudin Foundation, the Iranian-American Jewish Federation, the U.S.-Israel Bi-national Science Foundation and private donors. About NYU Langone Medical Center: NYU Langone Medical Center is one of the nation's premier centers of excellence in healthcare, biomedical research, and medical education. For over 168 years, NYU physicians and researchers have made countless contributions to the practice and science of health care. Today the Medical Center consists of NYU School of Medicine, including the Smilow Research Center, the Skirball Institute of Biomolecular Medicine, and the Sackler Institute of Graduate Biomedical Sciences; and the NYU Hospitals Center, including Tisch Hospital, a 705-bed acute-care general hospital, Rusk Institute of Rehabilitation Medicine, the first and largest facility of its kind, and NYU Hospital for Joint Diseases, a leader in musculoskeletal care, a Clinical Cancer Center and numerous ambulatory sites.

Jun 3, 2010

Health

Study finds epigenetic similarities between Wilms tumor cells and normal kidney stem cells

A detailed analysis of the epigenetics -- factors controlling when and in what tissues genes are expressed -- of Wilms tumor reveals striking similarities to stem cells normally found in fetal kidneys. These findings by Massachusetts General Hospital (MGH) Cancer Center researchers have revealed new cellular pathways that are critical for Wilms tumor development and may also apply to other pediatric cancers. The report appears in the June 4 Cell Stem Cell. Genetic mutations -- changes to the sequence of DNA molecules -- are known to underlie many types of cancer. But the role of epigenetics in tumor development is just beginning to be explored. The MGH team has been using advanced sequencing technology to investigate the role of chromatin, the structure that makes up chromosomes and consists of DNA wrapped around a protein backbone studded with molecules that can activate or suppress gene expression. "An organism has only one genome, but it has many epigenomes because different cell types organize their genome into chromatin in ways that allow them to express just the right set of genes," explains Bradley Bernstein, MD, PhD, of MGH Pathology and the MGH Cancer Center, senior author of the study. Earlier studies from Bernstein's team used cutting-edge sequencing technologies to identify chromatin structures characteristic of embryonic stem cells. They observed active versions of chromatin structures termed "domains" at genes with critical developmental functions and saw features of both active and repressed chromatin at "bivalent" genes that were not currently expressed but maintained the potential for activation. For the current study, Bernstein teamed with Miguel Rivera, MD, and Daniel Haber, MD, PhD, of the MGH Cancer Center, along with Aviva Presser Aiden, PhD, of the Broad Institute, to apply those powerful genomic technologies to cancer. The researchers chose to examine the epigenetics of Wilms tumor, a kidney cancer that usually occurs in children, because pediatric cancer cells are likely to have few genetic alterations, making it easier to identify epigenetic changes. Whole-genome chromatin screening of Wilms tumors, normal kidney tissues and fetal kidney tissues revealed that the chromatin of Wilms tumors contains the same types of active and bivalent chromatin structures identified in embryonic stem cells. Among the active genes were many well established regulators of kidney development, as well as a new set of genes that may be critical in tumor development. The presence of bivalent genes shows that normal developmental programs had been interrupted at an early stage in the tumor cells. In essence, Wilms cells give rise to a tumor by indefinitely continuing to behave like renal stem cells. While surgical removal and chemotherapy are successful for the majority of patients with Wilms tumor, current treatment protocols fail in up to 15 percent of patients, notes Rivera, who is co-lead author of the Cell Stem Cell report. "Epigenetic analysis has provided an unprecedented level of detail on the biology of Wilms tumor, allowing us to identify new genes that are likely to be important in this disease and to pinpoint specific defects in developmental pathways. Both of these findings may provide new avenues for therapy," he says. Rivera is an assistant professor of Pathology, and Bernstein an associate professor of Pathology at Harvard Medical School. Aviva Presser Aiden, PhD, of the Broad Institute is co-lead author of the report. Additional co-authors are Haber, Esther Rheinbay, Manching Ku, Erik Coffman and Than Truong, MGH Cancer Center; Sara Vargas, MD, Childrens Hospital Boston; and Eric Lander, DPhil, Broad Institute. Support for the study includes grants from the National Human Genome Research Institute, the National Cancer Institute, the Burroughs Wellcome Fund and the Howard Hughes Medical Institute. Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $600 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transplantation biology and photomedicine.

Jun 3, 2010

Health

UT Southwestern unveils next generation CT scanner that views whole organs in a heartbeat

DALLAS -- June 3, 2010 -- UT Southwestern Medical Center is the first site in North Texas to launch the next generation in CT scanners, which allow doctors to image an entire organ in less than a second or track blood flow through the brain or to a tumor -- all with less radiation exposure to patients. Aquilion One dynamic volume computed tomography (CT) can create a detailed 3-D movie of an organ in real time. That makes it particularly useful for quickly diagnosing strokes and heart attacks, for example, where diagnostic speed can be a critical factor in survival and recovery. Because the machine's technology can take continuous or intermittent images, UT Southwestern radiologists anticipate better visualization in neurology, trauma, whole body, lung, cardiac, vascular and pediatric studies. Other applications include providing distinctive capabilities in orthopaedic and joint studies, diagnosing renal function, and even vocal-cord analysis. For patients, the new technology can mean less time in a scanner and less exposure to radiation, said Dr. Phil Evans, associate vice president for clinical imaging and professor of radiology. "Dose has been a concern in the medical literature for a long time and people have been very concerned about it," said Dr. Evans, who directs UT Southwestern's Clinical Imaging Services. "One of the great things about this is that you can do a scan with about half the radiation dose and half the contrast media, so the dose is less and the image is better." Other scanners piece together strips of images to compile a complete picture, using four-, 16-, 32- or 64-slice machines. Aquilion One, manufactured by Toshiba, exposes patients to less radiation because one strip covers a larger area, therefore requiring fewer swaths overall and less time. The result can be as much as 80 percent less radiation in some cases, according to published research. Aquilion One uses 320 high-resolution X-ray detectors in each rotation. What takes 12 to 15 seconds for other scanners to complete takes only about a third of a second for the 320-slice machine. Aquilion One can take images continuously or intermittently, allowing doctors to see the heart pumping, or blood or medication working through the vascular system. "One of the most exciting things about this technology is the real-time ability to image changing anatomy," said Dr. Phillip Purdy, professor of radiology and neurological surgery. "We have been able to image physiology such as blood flow in parts of the brain, but now we can image the entire brain faster and more safely." The faster speed may also mean less required contrast materials and can also benefit patients who have difficulty remaining still, such as children, the elderly and trauma patients. Using Aquilion One, UT Southwestern physicians said they will be able to accurately diagnose a stroke or heart attack in about 20 minutes, as well as be able to gauge tissue damage. Currently, doctors often perform a battery of tests to confirm a heart attack -- an EKG, CT angiography, nuclear testing and catheterization -- which can take hours or even days. Other clinical applications include patients who can't get an MRI due to the presence of a pacemaker, or vocal-cord analysis capturing a patient phonating. The machine provides added flexibility in properly positioning patients with trauma or disabilities, and is sturdy enough to accommodate obese patients. UT Southwestern physicians also anticipate the Aquilion One device will be valuable in many of the medical center's unique research projects. For example, the ability to move backward and forward in time through the images may help researchers to visualize better the effects of tissue damage or vascular flow. "This has the potential to impact the daily medicine we currently practice and help us identify future clinical pathways," Dr. Evans said. "UT Southwestern is fortunate to have clinical experts and forward-looking researchers who will really be the ones to determine its best uses. Technology, even the best technology, still depends on the expertise of those using it." Visit http://www.utsouthwestern.org/radiology to learn more about UT Southwestern's clinical services in radiology. This news release is available on our World Wide Web home page at http://www.utsouthwestern.edu/home/news/index.html To automatically receive news releases from UT Southwestern via e-mail, subscribe at www.utsouthwestern.edu/receivenews

Jun 2, 2010

Health

Tobacco tax hike could curb smoking among those with alcohol, drug or mental disorders

A new study from the David Geffen School of Medicine at UCLA suggests that increasing cigarette taxes could be an effective way to reduce smoking among individuals with alcohol, drug or mental disorders. The study, published online in the American Journal of Public Health, found that a 10 percent increase in cigarette pricing resulted in an 18.2 percent decline in smoking among people in these groups. The findings demonstrate that increasing cigarette taxes could be a way to curb smoking, which is still the leading preventable cause of death in the United States, according to the study's lead author, Dr. Michael Ong, an assistant professor of medicine in the division of general internal medicine and health services research at the Geffen School of Medicine. "Whatever we can do to reduce smoking is critical to the health of the U.S.," said Ong, who is also a researcher at UCLA's Jonsson Cancer Center. "Cigarette taxes are used as a key policy instrument to get people to quit smoking, so understanding whether people will really quit is important. Individuals with alcohol, drug or mental disorders comprise 40 percent of remaining smokers, and there is little literature on how to help these people quit smoking." Prior research on the effect of cigarette pricing on smoking, which had been conducted using information from 1991, suggested that individuals with mental illness were less likely than other individuals to quit due to price increases. Unlike that research, however, the current study expanded the research to include people with alcohol and drug disorders. The researchers based their work on data from 7,530 individuals from the 2000-01 Healthcare for Communities Household Survey. Of those, 2,106 people, or 23 percent, had alcohol, drug or mental disorders during the previous year. Of that group, 43.8 percent were smokers -- a much higher proportion than among rest of the population. Though the researchers found that people with alcohol dependence did not cut down on cigarettes when prices rose, people with binge-drinking problems, substance-use disorders and mental disorders were significantly more likely to quit smoking if prices rose, as would occur with a cigarette tax increase. While the study does suggest that increasing cigarette prices through taxation could reduce smoking among individuals with alcohol, drug or mental disorders, the authors note that further study is needed to determine if recent cigarette price increases have reduced smoking among individuals with such disorders, and whether the identified association is causal. In addition to Ong, study authors were Qiong Zhou of UCLA and Hai-Yen Sung of UC San Francisco. The Robert Wood Johnson Foundation's Substance Abuse Policy Research Program, the Jonsson Cancer Center Foundation at UCLA, and the UCLA -- RAND NIMH Partnered Research Center for Quality Care funded this study. The General Internal Medicine and Health Services Research Division in the department of medicine at the David Geffen School of Medicine at UCLA provides a unique interactive environment for collaborative efforts between health services researchers and clinical experts with experience in evidence-based work. The division's 100-plus clinicians and researchers are engaged in a wide variety of projects that examine issues related to access to care, quality of care, health measurement, physician education, clinical ethics and doctor-patient communication. Researchers in the division have close working relationships with economists, statisticians, social scientists and other specialists throughout UCLA and frequently collaborate with their counterparts at the RAND Corp. and the Charles Drew University of Medicine and Science. For more news, visit the UCLA Newsroom and follow us on Twitter.

Jun 2, 2010

Health

Stanford/Packard study finds surprising disparity in where chronically ill kids hospitalized

STANFORD, Calif. -- Chronically ill children with private insurance are much less likely than those with public insurance, such as Medi-Cal, to be admitted to a California hospital offering specialized pediatric care, according to a new study by researchers at Lucile Packard Children's Hospital and the Stanford University School of Medicine. The study also shows that the likelihood of a chronically ill child being admitted to a specialty-care center varies wildly across the state. For example, chronically ill children in San Francisco and San Mateo counties were far more likely to be hospitalized at a pediatric specialty-care center than their counterparts just across the bay in Sonoma and Napa. These findings and several others in the study suggest that decisions about whether to refer a chronically ill child to a pediatric specialty-care hospital are in many cases driven by factors other than medical need. The study appears in the June issue of Pediatrics, which is also available online at http://pediatrics.aappublications.org. In examining hospital-discharge data from 1999 to 2007, the researchers concluded that the state's health leaders urgently need to review the policies and practices that determine where chronically ill kids are hospitalized. "There does not appear to be a coordinated and coherent system," said Paul Wise, MD, MPH, the study's senior author. "We were expecting some variation, but not this much." Pediatric specialty-care centers offer high levels of intensive care and a variety of clinical subspecialties. There are about 20 of these centers in California, including Santa Barbara Cottage Hospital and Riverside County Regional. Eight of these centers offer the most comprehensive range of services and are accredited as children's hospitals, among them Packard Children's. In 2007, pediatric beds at specialty-care centers were occupied 67 percent of the time by children with public insurance but only 32 percent of the time by privately insured children, the study reported. The reasons for the discrepancy are likely complex, the researchers said. But Wise, the Richard E. Behrman Professor of Child Health and Society at the School of Medicine and a pediatrician at Packard Children's, said he and his colleagues were planning to conduct a follow-up study to determine whether health maintenance organizations and other private insurers contributed to this disparity. It's possible, he said, that doctors are less likely to refer chronically ill kids with private insurance to pediatric specialty-care centers, whose services generally cost more than those of regular hospitals. The study also suggests that the state has been successful in helping low-income children with chronic illnesses get access to specialty-care services. However, the fact that public insurance is paying for the majority of these services makes the pediatric specialty-care centers, not to mention the children who depend on them, especially vulnerable to the state's current financial problems, said the lead author Lisa Chamberlain, MD, MPH, a pediatrician at Packard Children's and assistant professor of pediatrics at the medical school. "The specialty centers that see these patients are very dependent on the public financing of care," Chamberlain said. "With the unprecedented state budget crisis, Sacramento may look to balance the books by changing reimbursement patterns." How far chronically ill children lived from specialty-care centers also played a role in determining whether they would be hospitalized at one, but geography wasn't the only important factor, the researchers said, pointing to several counterintuitive findings. One is that chronically ill children in central California -- the counties of Mariposa, Madera, Fresno and Kings, which are among the poorest in the state -- were among the most frequent users of specialty-care centers statewide: 72 to 91 percent of these patients were discharged from such a center, even though there is only one, Children's Hospital Central California in Madera, serving the entire region. Chronically ill children in this area may have been going to a specialty-care center at higher rates because they were covered by public insurance and because of the relative paucity of nearby hospitals with inpatient services, Wise said. But in densely populated Los Angeles County, only 60 percent of chronically ill children were admitted to pediatric specialty-care centers, even though the county had by far the greatest concentration of such centers -- seven -- statewide. This relatively low admission rate may stem from a lack of pediatric beds at the specialty-care centers, but it could also have been the result of an abundance of nearby hospitals that offer inpatient care, the researchers said. In addition to the seven specialty-care centers, there were 97 other inpatient hospitals that care for children in the county. "I'm not sure that parents driving past a community hospital in L.A. would necessarily know that it doesn't provide the same kind of services that a children's specialty-care center would for their chronically sick child," Chamberlain said. Once their child is admitted to such a community hospital, the doctor may take into account factors unrelated to the patient's clinical condition, such as payer type and geography, in deciding whether to refer that patient to a specialty-care center, she said. The researchers noted that among children who had chronic illnesses and who died, one in six stayed for longer than two days in a non-specialty-care center -- a trend they called "worrisome." David Alexander, the president and CEO of the Lucile Packard Foundation for Children's Health and an adjunct clinical professor at the medical school, noted that one in eight U.S. children reside in California, making the issue one of national concern. "A greater number of hospital days are being filled by kids with chronic conditions," he said. "We need to find a way to provide these specialty care services to all children who need them." In addition to Wise and Chamberlain, the study's co-authors were Lynne Huffman, MD, associate professor of pediatrics, and Jia Chan, Pamela Mahlow and Kristen Chan, all current or former technical staff of the Center for Policy, Outcomes and Prevention in the Department of Pediatrics. The study was funded by the Lucile Packard Foundation for Children's Health. The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://mednews.stanford.edu. The medical school is part of Stanford Medicine, which includes Stanford Hospital & Clinics and Lucile Packard Children's Hospital. For information about all three, please visit http://stanfordmedicine.org/about/news.html. Ranked as one of the best pediatric hospitals in the nation by U.S.News & World Report, Lucile Packard Children's Hospital at Stanford is a 312-bed hospital devoted to the care of children and expectant mothers. Providing pediatric and obstetric medical and surgical services and associated with the Stanford University School of Medicine, Packard Children's offers patients locally, regionally and nationally the full range of health-care programs and services -- from preventive and routine care to the diagnosis and treatment of serious illness and injury. For more information, visit http://www.lpch.org.

Jun 2, 2010